(Q45116924)

9 December 2017

title

One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD. (English)

1 reference

chronic obstructive pulmonary disease

9 December 2017

main subject

1 reference

Anthony D'Urzo

1

1 reference

9 December 2017

Edward Kerwin

2

1 reference

9 December 2017

Stephen Rennard

3

1 reference

9 December 2017

Thomas He

4

1 reference

9 December 2017

Esther Garcia Gil

5

1 reference

9 December 2017

Cynthia Caracta

6

1 reference

9 December 2017

language of work or name

English

0 references

publication date

16 May 2013

1 reference

COPD: Journal of Chronic Obstructive Pulmonary Disease

9 December 2017

published in

1 reference

9 December 2017

volume

10

1 reference

9 December 2017

issue

4

1 reference

9 December 2017

page(s)

500-510

1 reference

Global burden of COPD: risk factors, prevalence, and future trends

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.791809

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.791809

Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.791809

A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.791809

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.791809

Standardisation of spirometry

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.791809

Cardiovascular morbidity and mortality in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.791809

Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.791809

Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.791809

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.791809

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.791809

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.791809

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.791809

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.791809

10.3109/15412555.2013.791809

21 January 2018

Identifiers

DOI

1 reference

release_qaanursevfappokr53mi6d6amu

9 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qaanursevfappokr53mi6d6amu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference